A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

NCT05886920 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: D3S-002-100
• Study Type: interventional
• Target: 67
• Locations: 3 countries
• Sites: 10

Brief Summary

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.

Conditions

Advanced Solid Tumors With MAPK Pathway Mutations

Keywords

Advanced solid tumors; mitogen-activated protein kinase; mutation

Outcome Measures

Primary Outcomes (3)

• Number of Participants With Adverse Events (AEs)

  First dose until 30 days after the last dose (or specified in the protocol)

• Maximum tolerated dose (MTD) based on Dose limiting toxicities (DLTs)

  First dose up to 24 months

• Recommended Phase 2 dose (RP2D)

  First dose up to 24 months

Secondary Outcomes (11)

• Part 1: D3S-002 maximum observed plasma concentration (Cmax)

  First dose up to 24 months

• Part 2: D3S-002 and D3S-001 maximum observed plasma concentration (Cmax)

  First dose up to 24 months

• Part 1: D3S-002 time to maximum plasma concentration (tmax)

  First dose up to 24 months

• Part 2: D3S-002 and D3S-001 time to maximum plasma concentration (tmax)

  First dose up to 24 months

• Part 1: D3S-002 half-life (t1/2)

  First dose up to 24 months

Study Arms (2)

D3S-002 Monotherapy

EXPERIMENTAL

Part 1: Dose Escalation, D3S-002 administered orally.

Drug: D3S-002

D3S-002 and D3S-001 Combination Therapy

EXPERIMENTAL

Part 2a: Dose Escalation, D3S-002 and D3S-001 administered orally. Part 2b: Dose Expansion, D3S-002 and D3S-001 administered orally.

Drug: D3S-002; Drug: D3S-001

Interventions

D3S-002 DRUG

Oral Tablet

D3S-002 Monotherapy; D3S-002 and D3S-001 Combination Therapy

D3S-001 DRUG

Oral Capsule

D3S-002 and D3S-001 Combination Therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Part 1: Subjects must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor with evidence of progressive disease.
• Part 2: Subjects must have a histologically or cytologically confirmed metastatic or locally advanced non-small cell lung cancer with evidence of PD.
• Subjects with non-small cell lung cancer (NSCLC) should have no known epidermal growth factor receptor (EGFR) mutations, ALK/ROS1/RET rearrangements, NTRK1/2/3 gene fusions, v-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutations, or MET exon 14 skipping mutations.
• Note: EGFR mutations include but are not limited to EGFR Exon19 Deletions, Exon21 p.L858R, Exon21 p.L861Q, Exon18 p.G719X, Exon20 p.S768I, Exon20 Insertions, Exon20 p.T790M. If other EGFR mutations are present, the Investigator should have a consultation with the sponsor's Medical Monitor before making the enrollment decision.
• Part1: Subjects must have documented mitogen-activated protein kinase (MAPK) pathway mutation(s) within the last 5 years identified by a local test on tumor tissue or blood (eg, rat sarcoma (RAS), rapidly accelerated fibrosarcoma (RAF), and MAPK kinase (MAPKK) mutations).
• Part 2: Subject must have documented Kirsten rat sarcoma viral oncogene (KRAS) p. glycine 12 to cysteine (p.G12C) mutation identified within the last 5 years by a local test on tumor tissue or blood.
• Note:
• All the local tests should clearly distinguish KRAS p.G12C from all other KRAS p.G12x variants. If not specified, subjects should have no known second KRAS mutations (including G12A, G12V, G12R, G13C, G12D, G12S, H95, Y96, Q61, and R68).
• Part 1: Subjects must be refractory to or intolerable with standard treatment, or have no available standard of care (SOC).
• Part 2: Subject must have received at least 1 line of prior standard of care systemic therapy for locally advanced and unresectable or metastatic disease, including KRAS p.G12C inhibitor.
• Note:
• Subjects should only have received 1 type of prior KRAS p.G12Ci treatment (including all types of KRAS p.G12C inhibitor which are either under investigation or in market, except D3S-001).
• During the prior KRAS p.G12C treatment, subject has achieved best response of partial or complete response regardless of KRAS p.G12Ci treatment duration, or stable disease for at least 6 months. However, subjects, who have stopped KRAS p.G12Ci therapy earlier than 6 months due to safety/tolerability reasons only, would be allowed. In such a situation, the Investigator should have a consultation with the Sponsor Medical Monitor before making the enrollment decision.
• Part 2: Subjects must have measurable disease per RECIST v1.1.
• Part 2: Subjects must agree to provide archival tumor tissue, if available, for genetic analysis. If archival tumor tissue is not available, or of insufficient quantity, an optional fresh biopsy is highly recommended.

You may not qualify if:

• Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.
• Part 2: subjects with mixed small-cell lung cancer, or large cell neuroendocrine histology, or sarcomatoid carcinoma.
• Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.
• Part 1: Uncontrolled or untreated brain metastasis.
• Part 2: Asymptomatic and stable brain metastases subjects will be eligible for enrollment per the following criteria.
• Treated or untreated brain metastases
• Neurologically asymptomatic
• Stable and not requiring steroids more than 10 mg/day of prednisone or equivalent for at least 4 weeks prior to the first dose of study medication.
• Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).
• Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.
• Any concurrent chemotherapy, immunotherapy, targeted therapy, cell therapy, biologic or hormonal therapy and any medical devices for cancer treatment.

Sponsors & Collaborators

• D3 Bio (Wuxi) Co., Ltd: lead

Study Sites (10)

D3 Bio Investigative Site

Detroit, Michigan, 48202, United States

Location

D3 Bio Investigative Site

New York, New York, 10029, United States

Location

D3 Bio Investigative Site

Blacktown, New South Wales, 2148, Australia

Location

D3 Bio Investigative Site

Bedford Park, South Australia, 5042, Australia

Location

D3 Bio Investigative Site

Nedlands, Western Australia, 6009, Australia

Location

D3 Bio Investigative Site

Beijing, Beijing Municipality, 100142, China

Location

D3 Bio Investigative Site

Guangzhou, Guangdong, 510080, China

Location

D3 Bio Investigative Site

Harbin, Heilong Jiang, 150081, China

Location

D3 Bio Investigative Site

Shanghai, Shanghai Municipality, 201801, China

Location

D3 Bio Investigative Site

Hangzhou, Zhejiang, 310009, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 24, 2023
• First Posted: June 2, 2023
• Study Start: July 10, 2023
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2028
• Last Updated: March 23, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

AU (3); US (2); CN (5)